Ella Jones, PhD

Specialist

Biography

Dr. Ella Jones has over 12 years of research experience in the private sector, pioneering the development of targeted molecules for cancer imaging. At UCSF, Dr. Jones has demonstrated her ability to conduct cross-modality imaging research. She has been funded by the NIH/NCI as the PI to develop preclinical optical/nuclear imaging tools for molecular characterization of premalignant breast cancer (R01CA135626), and PET/SPECT imaging agents for prostate cancer (R21CA122126 and R01CA140617: Subcontract PI), which has been successfully translated to human imaging.

In the past ten years, Dr. Jones has devoted her career in translational breast cancer research. Her current work focuses on the evaluation of the primary breast tumor and surrounding architecture using PET and MRI for prediction of treatment response and survival outcome. Dr. Jones has been working with OncoVision since 2014 on integrating the dedicated breast PET (dbPET) into the breast care workflow. Through this academic-industrial partnership (R01CA227763), a new software interface has been successfully developed to improved DICOM compatibility for the dbPET’s use in the clinic and by the I-SPY 2 TRIAL.

Dr. Jones is the PI on multiple projects building the infrastructure of the dbPET at UCSF and working with a team of oncologists, breast and nuclear imaging radiologists and physicists to ensure the success of the dbPET program. She provides the oversight of image quality control, acquisition, processing, and analysis, as well as radiotracer needs for breast cancer imaging from bench to clinical translation. She spearheaded the effort of the IND application for [F-18]fluoroestradiol (FES) and received approval from the FDA in mid-2017.

As the Chair of the NCI Quantitative Imaging Network (QIN) Clinical Trial Design and Development workgroup (CTDD-WG), Dr. Jones has direct access to quantitative imaging tools developed under the QIN, including those for radiomics analysis, auto-segmentation, tracer uptake quantification. As a member of the NCI NCTN-QIN oversight committee, Dr. Jones is committed to evaluating new quantitative imaging methods and translating their use in clinical decision making to improve disease outcomes.

Dr. Jones published over 50 peer-reviewed papers in high impact scientific journals, over 45 abstracts, and 7 patents in diagnostic imaging.

Education

Post-doctoral training, 1993 - Chemistry, University of Oxford
PhD, 1991 - Chemistry, University of California, Davis
BS, 1987 - Chemistry, University of San Francisco

Honors and Awards

Member, NCI NCTN-QIN Oversight Committee, 2020
Peer Reviewer, National Institute of Health, CTIS, 2019-2020
External Reviewer, KWF Kancer Bestrijding, 2019
External Reviewer, Western University, Canada, 2019
Vice Chair and Chair, NIH/NCI Quantitative Imaging Network - Clinical Trial Design and Development Workgroup, 2016-2020
Peer Reviewer, New York State Department of Health, 2015
Peer Reviewer, Department of Defense, Breast Cancer, 2014-2020
Poster Award Recipient, World Molecular Imaging Congress Meeting, 2013
Section Chair and Moderator, World Molecular Imaging Congress Meeting, 2013
Peer Reviewer, National Institute of Health, NIBIB Quantum Projects, 2010
Peer Reviewer, National Institute of Health, NIBIB Training SEP, 2010
Peer Reviewer, Department of Defense, Breast Cancer, 2010
Peer Reviewer, Department of Defense, Breast Cancer, 2009
Peer Reviewer, National Institute of Health, Challenge grants, 2009
Chair of the Solution Science and Engineering Network, Solutia, Inc., 2001
Chair of the Monsanto Technical Community, Phosphorus Chapter, Monsanto Chemical Company, 1997-2001
2 Outstanding Patent Awards, Mallinckrodt Medical, Inc., 1994
Assoicated Member of Balliol College, University of Oxford, 1991-1993
Outstanding Graduate Student Finalist, University of California, Davis, 1991
Non-resident Tuition Fellowship, University of California, Davis, 1987-1991
Student Award, American Chemical Society, 1987
Undergraduate Award in Analytical Chemistry, American Chemical Society, 1986

Publications

Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 Aug 24; 203645.
Liu G, Mitra D, Jones EF, Franc BL, Behr SC, Nguyen A, Bolouri MS, Wisner DJ, Joe BN, Esserman LJ, Hylton NM, Seo Y. Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images. J Digit Imaging. 2021 06; 34(3):630-636.
Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. Sci Rep. 2020 12 14; 10(1):21930.
Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. NPJ Breast Cancer. 2020 Nov 27; 6(1):63.
Arasu VA; Kim Pl; Li W; Strand F; McHargue C; Harnish R; Newitt DC; Jones EF; Glymour MM; Kornak J; Esserman LJ; Hylton NM and the ISPY2 investigators. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2− Patients. Journal of Breast Imaging. 2020.
Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators . Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients. J Breast Imaging. 2020 Aug; 2(4):352-360.
Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. Cancers (Basel). 2020 Jun 09; 12(6).
Jones EF, Buatti JM, Shu HK, Wahl RL, Kurland BF, Linden HM, Mankoff DA, Rubin DL, Tata D, Nordstrom RJ, Hadjiyski L, Holdhoff M, Schwartz LH.. Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. Tomography. 2020; 6(2):60-64.
Nguyen A, Vignesh A, Strand F, Wen L, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LE, Newitt DN, Hylton NM. Comparison of segmentation methods in assessing background parenchymal enhancement as a biomarker for response to neoadjuvant therapy. Tomography. 2020; 6(2):101-110.
Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM. . Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial. Tomography. 2020; 6(2):77-85.
McNitt-Gray M, Napel S, Jaggi A, Mattonen SA, Hadjiiski L, Muzi M, Goldgof D, Balagurunathan Y, Pierce LA, Kinahan PE, Jones EF, Nguyen A, Virkud A, Chan HP, Emaminejad N, Wahi-Anwar M, Daly M, Abdalah M, Yang H, Lu L, Lv W, Rahmim A, Gastounioti A, Pati S, Bakas S, Kontos D, Zhao B, Kalpathy-Cramer J, Farahani K. . Standardization in Quantitative Imaging: A Multicenter Comparison of Radiomic Features from Different Software Packages on Digital Reference Objects and Patient Data Sets. Tomography. 2020; 6(2):118-128.
Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM.. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer. Tomography. 2020; 6(2):216-222.
Hathi DK, Jones EF. 68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Radiol Imaging Cancer. 2019 09; 1(1):e194003.
Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, I-SPY 2 Consortium , Esserman LJ, Hylton NM. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. J Magn Reson Imaging. 2019 12; 50(6):1742-1753.
Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12.
Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G. Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clin Pharmacol Ther. 2019 07; 106(1):148-163.
Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis. NPJ Breast Cancer. 2018; 4:24.
Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1219-1235.
Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 01; 5(1):011014.
L. Singer, E. Jones, D. Newitt, J. Kornak, N. Hylton, C.C. Park. Dynamic Contrast-Enhanced MRI in Monitoring Changes in Tumor-Associated Stroma During Treatment With Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. International Journal of Radiation Oncology • Biology • Physics. 2017 Oct 1; 99(2):s194.
Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107.
Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159.
Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones EF, Bodeker KL, Buatti JM. Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey. Tomography. 2016 Dec; 2(4):276-282.
Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network . Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387.
Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, VanBrocklin HF. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem. 2016 06 23; 59(12):5684-94.
Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM. Variability and bias assessment in breast ADC measurement across multiple systems. J Magn Reson Imaging. 2016 10; 44(4):846-55.
Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM. Design of a breast phantom for quantitative MRI. J Magn Reson Imaging. 2016 09; 44(3):610-9.
Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047.
Drake CR, Estévez-Salmerón L, Gascard P, Shen Y, Tlsty TD, Jones EF. Towards aspirin-inspired self-immolating molecules which target the cyclooxygenases. Org Biomol Chem. 2015 Dec 07; 13(45):11078-86.
Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol. 2014 Feb; 7(1):130-7.
McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. J Magn Reson Imaging. 2014 May; 39(5):1308-13.
Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969.
Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9.
Mongan J, Rathnayake S, Fu Y, Wang R, Jones EF, Gao DW, Yeh BM. In vivo differentiation of complementary contrast media at dual-energy CT. Radiology. 2012 Oct; 265(1):267-72.
Tucker RM, Parcher BW, Jones EF, Desai TA. Single-injection HPLC method for rapid analysis of a combination drug delivery system. AAPS PharmSciTech. 2012 Jun; 13(2):605-10.
Jones EF, Schooler J, Miller DC, Drake CR, Wahnishe H, Siddiqui S, Li X, Majumdar S. Characterization of human osteoarthritic cartilage using optical and magnetic resonance imaging. Mol Imaging Biol. 2012 Feb; 14(1):32-9.
Davison HR, Taylor S, Drake C, Phuan PW, Derichs N, Yao C, Jones EF, Sutcliffe J, Verkman AS, Kurth MJ. Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice. Bioconjug Chem. 2011 Dec 21; 22(12):2593-9.
Drake CR, Miller DC, Jones EF. Activatable Optical Probes for the Detection of Enzymes. Curr Org Synth. 2011 Aug; 8(4):498-520.
Cattaruzza F, Lyo V, Jones E, Pham D, Hawkins J, Kirkwood K, Valdez-Morales E, Ibeakanma C, Vanner SJ, Bogyo M, Bunnett NW. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology. 2011 Nov; 141(5):1864-74.e1-3.
David Pham, Ling Zhang, Bo Chen, Ella Fung Jones. Biopolymer, Dendrimer, and Liposome Nanoplatforms for Optical Molecular Imaging. Nanoplatform-Based Molecular Imaging. 2011 Mar 28; 183-196.
Elizabeth Noey, Jeff C. Curtis, Sylvia Tam, David M. Pham, Ella F. Jones. Synthesis and Ligand-Exchange Reactions of a Tri-Tungsten Cluster with Applications in Biomedical Imaging. Journal of Chemical Education. 2011 Mar 23; 88(6):793-797.
Noey, S.; Tam., S.; Pham, D. M.; Curtis, J.; Jones, E.F. . Tungsten Cluster Synthesis and Subsequent Ligand-Exchange Reactions. J. Chem. Ed. 2011; 88(6):793-797.
Meier R, Krug C, Golovko D, Boddington S, Piontek G, Rudelius M, Sutton EJ, Baur-Melnyk A, Jones EF, Daldrup-Link HE. Indocyanine green-enhanced imaging of antigen-induced arthritis with an integrated optical imaging/radiography system. Arthritis Rheum. 2010 Aug; 62(8):2322-7.
Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med. 2009 Dec; 50(12):2042-8.
Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, Coussens LM, Franc BL. Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem. 2009 Jan 15; 17(2):653-9.
Ella F. Jones, Henry F. Van Brocklin. Bruce H. Hasegawa, PhD (1951–2008). Journal of Nuclear Cardiology. 2008 Sep 1; 15(5):733-734.
Boddington S, Sutton EJ, Jones E, Purcell DD, Henning TD, Tavri S, Meier R, Sista A, Fu Y, Daldrup-Link H. Improved fluorescence of indocyanine green in vitro and in vivo after simple cooling procedures. Contrast Media Mol Imaging. 2008 Sep-Oct; 3(5):191-7.
Ella Jones, Jiang He, Henry VanBrocklin, Benjamin Franc, Youngho Seo. Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging. Current Nanoscience. 2008 Feb 1; 4(1):17-29.
Gao Q, Reynolds GE, Innes L, Pedram M, Jones E, Junabi M, Gao DW, Ricoul M, Sabatier L, Van Brocklin H, Franc BL, Murnane JP. Telomeric transgenes are silenced in adult mouse tissues and embryo fibroblasts but are expressed in embryonic stem cells. Stem Cells. 2007 Dec; 25(12):3085-92.
Fung EY, Olmstead MM, Vickery JC, Balch AL . Glowing gold rings: Solvoluminescence from Planar Trigold(I) Complexes. Coord. Chem. Rev. 1998; 171:151.
Vickery JC, Olmstead MM, Fung EY, Balch AL. Solvent-Stimulated Luminescence from the Supramolecular Aggregation of a Trinuclear Gold(I) Complex that Displays Extensive Intermolecular Au…Au Interactions. Angew. Chem., Int. Ed. Engl. 1997; 36:1179.
Lau KW, Hu NM, Yen MH, Fung EY, Grzybicki S, Matamoros R, Curtis JC . Solvent, Electrolyte and Solute Shape Effects on Optical Electron Transfer in Mixed-Valence Ruthenium Ammine Dimers. Inorg. Chim. Acta. 1994; 226:137.
Salaymeh F, Berhane S, Yusof R, de la Rosa R, Fung EY, Matamoros R, Lau KW, Zheng Q, Kober EM, Curtis JC . Electronic Coupling in Mixed-Valence Binuclear Ruthenium Ammine Complexes as Probed by an Electrochemical Method and an Extension of R. S. Mulliken's Theory of Donor-Acceptor Interactions. Inorg. Chem. 1993; 32:3895.
Balch AL, Fung EY, Nagle JK, Olmstead MM, Rowley SP . Lead(II)/Platinum(II) Complexes with and without Pb-Pt Interactions. Inorg. Chem. 1993; 32:3295.
Balch AL, Davis BJ, Fung EY, Olmstead MM . Palladium-thallium Interactions in Dinuclear Complexes with Structural Components that Place the Two Metal Centers in Close Proximity. Inorg. Chim. Acta. 1993; 212:149.
Balch AL, Fung EY, Olmstead MM . Polynuclear ((Diphenylphosphino)-methyl)-phenylarsine Bridged Complexes of Gold(I). Bent Chains of Gold(I) and a Role for Au(I)-Au(I) Interactions in Guiding a Reaction. J. Am. Chem. Soc. 1990; 112:5181.
Balch AL, Fung EY, Olmstead MM . Preparation and Structure of Two Polynuclear Aggregate Obtained Using the Metalloligand {ClAuPPh2CH2}2AsPh. Inorg. Chem. 1990; 29:3203.
Balch AL, Fung EY . Two- and Four-Coordinate Gold(I) Complexes of Tris(2-diphenylphosphinoethyl)phosphine. Inorg. Chem. 1990; 29:4764.
Fung EY, Chua A, Curtis JC . Evidence for a Specific Solvent-Solute Interaction as a Major Contributor to the Excited-State Distortion of the Emitting Charge-Transfer State in the Complex (bpy)2RuII(CN)2. Inorg. Chem. 1988; 27:1294.
Chang JP, Fung EY, Curtis JC . Evidence for Specific Solvent-Solute Interactions as a Major Contributor to the Franck-Condon Energy in Intervalence-Transfer Absorptions of Ruthenium Amine Complexes. Inorg. Chem. 1986; 25:4233.